Technology

Akari Therapeutics

$2.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (+0.34%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AKTX and other stocks, options, and ETFs commission-free!

About AKTX

Akari Therapeutics plc ADR (0.01 USD), also called Akari Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom. The listed name for AKTX is Akari Therapeutics plc ADR (0.01 USD).

CEO
Clive Stuart Richardson
Employees
10
Headquarters
London, London & South East
Founded
2004
Market Cap
110.10M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
612.35K
High Today
$3.08
Low Today
$2.67
Open Price
$2.89
Volume
272.52K
52 Week High
$3.76
52 Week Low
$0.87

Collections

AKTX Earnings

Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 31, Pre-Market

You May Also Like

FBMS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure